| FOA Number | Participating Organization | Clinical Trial | Activity Code | Application Due Date |
|---|---|---|---|---|
| PAR-22-109 | National Cancer Institute | Optional | R21 | 1. June 16, 2023 2. October 16, 2023 3. February 16, 2024 4. June 16, 2024 5. October 16, 2024 6. February 16, 2025 |
Others
NIH Grants & Funding
| FOA Number | Participating Organizations | Title | Clinical Trial | Activity Code | Application Due Date |
|---|---|---|---|---|---|
| PAR-22-084 | National Cancer Institute (NCI) | Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed) | Not allowed | R21 | ClosedJune 16, 2023 | October 16, 2023 | February 16, 2024 | June 16, 2024 | October 16, 2024 | February 16, 2025 |
| RFA-AI-21-078 | National Institute of Allergy and Infectious Diseases (NIAID) | RePORT International Coordinating Center (RICC) | Not allowed | U01 | ClosedMarch 17, 2022 |
| PAR-22-083 | National Cancer Institute (NCI) | Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed) | Not allowed | R01 | ClosedJune 05, 2023 | October 05, 2023 | February 05, 2024 | June 05, 2024 | October 05, 2024 | February 05, 2025 |
| RFA-CA-23-033 | National Cancer Institute (NCI) | Implementation Science for Cancer Control in People Living with HIV in Low- and Middle-Income Countries (U01 Clinical Trial Optional) | Optional | U01 | ClosedDecember 16, 2023 |
| PAR-22-054 | Office of Strategic Coordination (Common Fund) | Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program | Not allowed | X01 | ClosedFebruary 23, 2022 |
| RFA-CA-24-005 | National Cancer Institute (NCI) | Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional) | Optional | U01 | ClosedOctober 13, 2023 |
| PAR-21-035 | National Cancer Institute (NCI) | Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) | Required | R01 | ClosedJanuary 8, 2024 |
| RFA-DA-22-045 | National Center for Complementary and Integrative Health (NCCIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Aging (NIA), National Institute on Drug Abuse (NIDA) | HEAL Initiative: Exploratory Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic | Not allowed | R21 | ClosedMarch 10, 2022 |
| PAR-21-190 | National Cancer Institute (NCI) | Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) | Optional | R01 | ClosedNovember 05, 2023 | March 07, 2024 |
| PAR-23-158 | National Institute on Drug Abuse (NIDA) | Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH) Required) | Basic Experimental Studies with Humans are required. | R61/R33 | June 21, 2023 | October 09, 2023 | March 13, 2024 | June 20, 2024 | October 09, 2024 | March 13, 2025 | June 20, 2025 | October 09, 2025 | March 13, 2026 |
| RFA-DK-21-004 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | The Autoantigens and Neoantigens Function in the Etiology and Pathophysiology of Type 1 Diabetes | Optional | R01 | Closed22 June 2021 and 9 March 2022 |
| RFA-DA-24-024 | National Institute on Drug Abuse (NIDA) | Advancing Psychedelics Research for Treating Addiction (R61/R33 Clinical Trial Required) | Required | R61/R33 | ClosedNovember 02, 2023 |
| RFA-CA-22-056 | National Cancer Institute (NCI) | Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R01 Clinical Trial Not Allowed) | Not allowed | R01 | ClosedDecember 16, 2023 |
| RFA-CA-22-057 | National Cancer Institute (NCI) | Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R21 Clinical Trial Not Allowed) | Not allowed | R21 | ClosedDecember 16, 2023 |
| PAR-22-162 | National Cancer Institute (NCI) | Research Opportunities in Established Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed) | Not allowed | U01 | Closed July 28, 2023 | February 28, 2024 | July 29, 2024 | February 28, 2025 |
| PAR-21-329 | National Cancer Institute (NCI) | Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) | Optional | R01 | ClosedJune 05, 2023 | October 05, 2023 | February 05, 2024 | June 05, 2024 | October 05, 2024 |
| PAR-22-106 | National Cancer Institute (NCI) | Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed) | Not allowed | R03 | ClosedJune 16, 2023 | October 16, 2023 | February 16, 2024 | June 16, 2024 | October 16, 2024 | February 16, 2025 |
| PAR-22-105 | National Cancer Institute (NCI) | Dissemination and Implementation Research in Health (R01 Clinical Trial Optional) | Optional | R01 | ClosedJune 05, 2023 | October 05, 2023 | February 05, 2024 | June 05, 2024 | October 05, 2024 | February 05, 2025 |
| NOT-CA-23-059 | National Cancer Institute (NCI) | Notice of Special Interest (NOSI): Administrative Supplements for the Dog Oncology Grant Supplement (DOGS) Program | Optional | P01, P50, R01, R37, U01, U19, U24, U54 | ClosedJune 16, 2023 |
| PAR-22-216 | National Cancer Institute (NCI) | NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) | Optional | R21 | June 12, 2023 | October 10, 2023 | February 13, 2024 | June 12, 2024 | October 10, 2024 | February 13, 2025 | June 12, 2025 |
| PAR-22-243 | National Cancer Institute (NCI) | Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional) | Optional | R01 | June 05, 2023; October 05, 2023; February 05, 2024; June 05, 2024; October 05, 2024; February 05, 2025; June 05, 2025 |
| RFA-NS-22-034 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Cancer Institute (NCI), National Center for Advancing Translational Sciences (NCATS), National Center for Complementary and Integrative Health (NCCIH), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA) | HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment | Not allowed | R01 | ClosedMarch 02, 2022 to October 02, 2024 |
| RFA-MH-22-136 | National Institute of Mental Health (NIMH), National Institute on Aging (NIA) | Social disconnection and Suicide Risk in Late Life | Optional | R21 | ClosedMarch 15, 2022 and October 15, 2022 |
| PAR-22-055 | National Institute of Neurological Disorders and Stroke (NINDS) | Data Harmonization, Curation and Secondary Analysis of Existing Clinical Datasets | Not allowed | R61/R33 | ClosedMarch 15, 2022; March 14, 2023; and March 14, 2024 |
| PA-21-199 | National Institute of Mental Health (NIMH) | Research on Autism Spectrum Disorders | Optional | R03 | ClosedOctober 16, 2021 to February 16, 2024 |
| PA-21-200 | National Institute of Mental Health (NIMH) | Research on Autism Spectrum Disorders | Optional | R21 | ClosedOctober 16, 2021 to February 16, 2024 |
| PA-21-201 | National Institute of Mental Health (NIMH) | Research on Autism Spectrum Disorders | Optional | R01 | Closed5 October 2021 to 5 February 2024 |
| PAR-21-210 | National Institute of Mental Health (NIMH) | Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes | Required | R01 | ClosedOctober 5, 2021 to February 5, 2024 |
| PAR-21-211 | National Institute of Mental Health (NIMH) | Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes | Required | R34 | ClosedOctober 16, 2021 to February 16, 2024 |
| PAR-21-122 | National Institute of Neurological Disorders and Stroke (NINDS) | Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies | Not allowed | R61/R33 | ClosedOctober 19, 2021 to February 20, 2024 |
| PAR-21-123 | National Institute of Neurological Disorders and Stroke (NINDS) | Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery | Not allowed | R61/R33 | ClosedOctober 19, 2021 to February 20, 2024 |
| PAR-21-124 | National Institute of Neurological Disorders and Stroke (NINDS) | Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification | Not allowed | R61/R33 | ClosedOctober 19, 2021 to February 20, 2024 |
International Funding Opportunities
